SOURCE: Zenosense, Inc.

Zenosense, Inc.

November 04, 2014 08:30 ET

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

VALENCIA, SPAIN--(Marketwired - Nov 4, 2014) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense," the "Company"), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce the manufacturing of a pre-commercial prototype device to be evaluated for the detection of lung cancer in exhaled breath ("Device").

Prototyping manufacture is well advanced. The work has been undertaken by the Company's contracted development partner Zenon Biosystem ("Zenon"), which is part of the Sgenia group. In line with the protocol design for an anticipated lung cancer detection trial to be held in a clinical setting, two pre-commercial Devices are currently being manufactured of the same design to ensure reproducibility of results. The completed Devices are expected to be ready during the second half of the current month.

The Device incorporates components designed to filter out Volatile Organic Compounds ("VOCs") not of interest in order to optimize the detection of target VOC biomarkers found in exhaled breath and associated with the incidence of lung cancer.

These components and their elements include molecular sieves incorporated in complementary layered and mixed sensor structures to screen incoming VOCs, and nanometric sensing mesh to maximize the detective area. During this optimization process Zenon has developed new metal oxide materials and combinations of metal oxides that cannot be found in commercially available sensors. A complementary quartz crystal sensor employing a gas sorbent substrate has also been designed, along with a micro gas chromatography chip, for pre-detection screening. All components are of a relatively low cost consistent with the Company's intent to create cost effective products.

The Company looks forward to the testing of the Devices in the planned lung cancer detection trial. Work is ongoing by Zenon to establish the necessary collaborations to carry out the trial. The Company believes that a cost-effective lung cancer detector analyzing exhaled breath proven as meeting or exceeding the accuracy of low dose Computed Tomography (CT) scanning will have wide appeal and be in significant demand.

About Zenosense, Inc.

Zenosense, Inc. is a detection device development company based in Valencia, Spain. Its mission is to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients and market and sell these products to hospitals and primary healthcare facilities. Two devices are currently under development; a device intended to detect the Methicillin-resistant Staphylococcus aureus "Super-Bug" (MRSA); and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness.

Find out more at

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed on filed on March 26, 2014, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Statements concerning the development of both the MRSA device and the lung cancer device have been made based on information obtained from Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.

Contact Information